The niacin skin flush test in schizophrenia: A replication study

International Journal of Clinical Practice

Volumn 55, Issue 6, 2001, Pages 368-370

  Purl, B K ^a,c   Das, I ^b   Kidane, L ^b   Richardson, A J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; NICOTINIC ACID METHYL ESTER;

ADULT; AGE; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENDER; HUMAN; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PUBLISHING; RECORDING; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SKIN TEST; TIME;

ADMINISTRATION, TOPICAL; ADULT; ANALYSIS OF VARIANCE; ARACHIDONIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; NIACIN; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN TESTS;

EID: 0034903910     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 3-7.
2. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
3. 2 activity in schizophrenia: a replication study. Biol Psychiatry 1990; 28: 495-501.
4. 2 activity in schizophrenia. Schizophr Res 1995; 16: 1-6.
5. 2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 109-113.
6. Ross BM, Hudson C, Erlich J el al. Increased phospholipid breakdown in schizophrenia: evidence for the involvement of a calcium-independent phospholipase A2. Arch Gen Psychiatry 1997; 54: 487-494.
7. Glen AI, Glen EM, Horrobin DF et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
8. Glen AIM, Cooper SJ, Rybakowski J et al. Membrane fatty acids, niacin Hushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996:55:9-15.
9. Mahadik SP, Shendarkar NS, Scheffer RE et al. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukol Essent Fatty Acids 1996:55:65-70.
10. Mahadik SP, Mukherjee S. Cultured skin fibroblasts as a cell model for investigating schizophrenia. J Psychiatr Res 1996; 30: 421-439.
11. Pangerl AM, Slcudle A, Jaroni HW et al. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol Psychiatry 1991 ; 30: 837-840.
12. Pettegrew JW. Keshavan MS, Panchalingam K et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in firstepisode, drug-naive schizophrenics: a pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48: 563-568.
13. Horrobin DF. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. J Orlhomolec Psychiatry 1980:9: 33-34.
14. Rybakowski J, Weterle R. Niacin test in schizophrenia and affective illness. Biol Psychiatry 1991; 29: 834-836.
15. Morrow JD, Awad JA, Dates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812-815.
16. Ward PE. Sutherland J, Glen EMT, Glen AIM. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998; 29: 269-274.
17. SPSS Inc. SPSS for Windows. Chicago: SPSS, 1998.
18. Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 71-75.
19. Ward PE, Glen AIM. Oral and topical niacin flush testing in schizophrenia. In: Peet M, Glen I, Horrobin DF, Eds. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press, 1999; 139-144.
20. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 141-167.